platelet rich plasma effect on plantar fasciitis

evaluating the efficacy of injection of Platelet Rich Plasma in treatment of plantar fasciitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014011316201N1

Enrollment

Registered

2014-01-19

Start date

2014-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

plantar fasciitis. Plantar fascial fibromatosis

Interventions

2cc platelet rich plasma/1cc methyl prednisolon40 mg+ 1 cc lidocain 2%.

Treatment - Drugs

2cc platelet rich plasma/1cc methyl prednisolon40 mg+ 1 cc lidocain 2%

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with unilateral PF or pain prominent in one foot; intractable pain for a minimum of 3 months’ duration ; a VAS score of at least 4 at the insertion of the plantar fascia on calcaneus taking the first step in the morning. Exclusion criteria: usage of NSAIDs within 48 hours of procedure; corticosteroid injection at treatment site within 1 month; having any other associated pathology involving the lower limb; abnormal ESR or CRP level; any systemic disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: baseline, 3 weeks, 8 weeks. Method of measurement: visual analogue score.;Disability. Timepoint: baseline, 3 weeks and 8 weeks. Method of measurement: persian version of Foot and Ankle Ability Measure(FAAM).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Karimian

Physical Medicine and Rehabilitation ward, Shiraz University of Medical Sciences

karimian_h@sums.ac.ir+98 71 1231 9040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026